Immunosuppression used to treat GVHD after SOT in addition to corticosteroids
| Orthotopic liver/LK . | Intestine/MV . | Lung/HL . | Kidney/KP . |
|---|---|---|---|
| ATG (47)10,27,49,50,53,58-70 | ATG (1)71 | ATG (5)11-13,72,73 | ATG (1)9 |
| Alemtuzumab (5)10,64,74,75 | Alemtuzumab (3)71,76 | Alemtuzumab (1)73 | Mycophenolate (1)77 |
| Basiliximab (8)53,65,70,75,78-80 | Basiliximab (2)71,76 | Basiliximab (2)73,81 | IVIG (1)7 |
| Daclizumab (4)64,66,74,82 | Daclizumab (1)83 | Azathioprine (2)12,84 | AlloHCT (1)85 |
| Muromonab-CD3 (8)58,62,67 | Sirolimus (2)71,76 | Immunoglobulin (1)72 | |
| Cyclophosphamide (2)10,58 | Immunoglobulin (2)76 | Infliximab (1)14 | |
| Azathioprine (1)86 | Rituximab (4)71,76 | Ruxolitinib (1)87 | |
| Topical GI steroids (3)10 | Alefacept (2)71,76 | ECP (3)14,72,81 | |
| Immunoglobulin (4)88-90 | Infliximab (3)71,76 | ||
| Rituximab (2)74,78 | ECP (1)71 | ||
| Alefacept (4)10,68 | Splenectomy (1)76 | ||
| Infliximab (1)59 | Plasmapheresis (1)76 | ||
| Etanercept (2)10,91 | |||
| Vedolizumab (1)10 | |||
| Ruxolitinib (3)10,87 | |||
| ECP (1)10 | |||
| Thymosin alpha (3)66,88 | |||
| Ex vivo host CD8+ T-cell expansion (1)75 | |||
| AlloHCT (8)10,60,92-96 |
| Orthotopic liver/LK . | Intestine/MV . | Lung/HL . | Kidney/KP . |
|---|---|---|---|
| ATG (47)10,27,49,50,53,58-70 | ATG (1)71 | ATG (5)11-13,72,73 | ATG (1)9 |
| Alemtuzumab (5)10,64,74,75 | Alemtuzumab (3)71,76 | Alemtuzumab (1)73 | Mycophenolate (1)77 |
| Basiliximab (8)53,65,70,75,78-80 | Basiliximab (2)71,76 | Basiliximab (2)73,81 | IVIG (1)7 |
| Daclizumab (4)64,66,74,82 | Daclizumab (1)83 | Azathioprine (2)12,84 | AlloHCT (1)85 |
| Muromonab-CD3 (8)58,62,67 | Sirolimus (2)71,76 | Immunoglobulin (1)72 | |
| Cyclophosphamide (2)10,58 | Immunoglobulin (2)76 | Infliximab (1)14 | |
| Azathioprine (1)86 | Rituximab (4)71,76 | Ruxolitinib (1)87 | |
| Topical GI steroids (3)10 | Alefacept (2)71,76 | ECP (3)14,72,81 | |
| Immunoglobulin (4)88-90 | Infliximab (3)71,76 | ||
| Rituximab (2)74,78 | ECP (1)71 | ||
| Alefacept (4)10,68 | Splenectomy (1)76 | ||
| Infliximab (1)59 | Plasmapheresis (1)76 | ||
| Etanercept (2)10,91 | |||
| Vedolizumab (1)10 | |||
| Ruxolitinib (3)10,87 | |||
| ECP (1)10 | |||
| Thymosin alpha (3)66,88 | |||
| Ex vivo host CD8+ T-cell expansion (1)75 | |||
| AlloHCT (8)10,60,92-96 |
Each listed immunosuppressive agent is followed by the total number of cases of GVHD in parentheses that are reported to have been treated with this agent.
ECP, extracorporeal photopheresis; HL, combined heart-lung transplantation; KP, combined kidney-pancreas transplantation; LK, combined liver kidney transplantation; MV, multivisceral transplantation.